These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36445366)

  • 1. Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States.
    Ream MA; Lam WKK; Grosse SD; Ojodu J; Jones E; Prosser LA; Rosé AM; Comeau AM; Tanksley S; Powell CM; Kemper AR
    Genet Med; 2023 Feb; 25(2):100330. PubMed ID: 36445366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study.
    Muenzer J; Burton BK; Harmatz P; Gutiérrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
    Mol Genet Metab; 2022; 137(1-2):127-139. PubMed ID: 36027721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
    Wraith JE; Scarpa M; Beck M; Bodamer OA; De Meirleir L; Guffon N; Meldgaard Lund A; Malm G; Van der Ploeg AT; Zeman J
    Eur J Pediatr; 2008 Mar; 167(3):267-77. PubMed ID: 18038146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II.
    Muenzer J; Burton BK; Harmatz P; Gutiérrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
    Mol Genet Metab; 2022; 137(1-2):92-103. PubMed ID: 35961250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
    Gusarova VD; Smolov MA; Lyagoskin IV; Degterev MB; Rechetnik EV; Rodionov AV; Pantyushenko MS; Shukurov RR
    BioDrugs; 2023 May; 37(3):375-395. PubMed ID: 37014547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review.
    Al-Hertani W; Pathak RR; Evuarherhe O; Carter G; Schaeffer-Koziol CR; Whiteman DAH; Wright E
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
    Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK
    Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).
    Kubaski F; Vairo F; Baldo G; de Oliveira Poswar F; Corte AD; Giugliani R
    Curr Pharm Des; 2020; 26(40):5100-5109. PubMed ID: 33138761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
    Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-Based Newborn Screening for Mucopolysaccharidosis Type II in Illinois: The First Year Experience.
    Burton BK; Hoganson GE; Fleischer J; Grange DK; Braddock SR; Hickey R; Hitchins L; Groepper D; Christensen KM; Kirby A; Moody C; Shryock H; Ashbaugh L; Shao R; Basheeruddin K
    J Pediatr; 2019 Nov; 214():165-167.e1. PubMed ID: 31477379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newborn screening for mucopolysaccharidosis type II: Lessons learned.
    Burton BK; Shively V; Quadri A; Warn L; Burton J; Grange DK; Christensen K; Groepper D; Ashbaugh L; Ehrhardt J; Basheeruddin K
    Mol Genet Metab; 2023; 140(1-2):107557. PubMed ID: 36907694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC; Abrahão L; Schwartz IV; Lourenço CM; Santos ES; Zanetti A; Tomanin R; Scarpa M; Giugliani R; Leistner-Segal S
    Gene; 2013 Sep; 526(2):150-4. PubMed ID: 23707223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome.
    Julien DC; Woolgar K; Pollard L; Miller H; Desai A; Lindstrom K; Kishnani PS
    Front Immunol; 2020; 11():1000. PubMed ID: 32508845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points.
    Glamuzina E; Fettes E; Bainbridge K; Crook V; Finnegan N; Abulhoul L; Vellodi A
    J Inherit Metab Dis; 2011 Jun; 34(3):749-54. PubMed ID: 21327479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.
    Żuber Z; Różdżyńska-Świątkowska A; Jurecka A; Tylki-Szymańska A
    PLoS One; 2014; 9(1):e85074. PubMed ID: 24454794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.